Arcellx Inc (ACLX)
ACLX
Cell Therapy
BiotechSign Signal Grade
F
Signal Grade
34.7/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
50
Short Interest
70
Pipeline Overview
- Therapeutic Focus
- Cell Therapysrc
Clinical Trial Activity
5
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
3 Phase 1, 1 Phase 2, 1 Phase 3
Trial Phase Breakdown
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Short Interest
23.54%
Float Shorted
10.9
Days to Cover
HIGH
Squeeze Risk
-1.7%
SI Change
STABLE
Trend
9,119,451
Shares Short
Short interest: 23.54% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0. — J Immunother Cancer 2026 Sep 21 PMID 42767771
- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial. — Nat Med 2026 Aug PMID 42487061
- Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma. — Clin Lymphoma Myeloma Leuk 2026 Aug PMID 42315418
- Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis. — Am J Hematol 2026 Aug PMID 42157444
- Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma. — Bone Marrow Transplant 2026 Jul PMID 42115674
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Arcellx Inc.
Full ACLX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.